Meloabalin besylate oral soluble film agent and preparation method thereof

By using aqueous ethanol solution and hydroxypropylmethylcellulose in the preparation of milobalpharin benzenesulfonate, the export membrane solvent was prepared, which solved the problem of dysphagia of oral preparations in the prior art, and realized the drug in the oral cavity. Fast disintegration and easy to swallow.

CN118948808AActive Publication Date: 2024-11-15SHANDONG UNIV

Patent Information

Application Number
CN202411079481.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-15
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

The existing dosage forms of milobalbarin benzenesulfonate are mainly concentrated in oral preparations. It is difficult for the elderly, children and patients with dysphagia to take, and there is a lack of rapid disintegration oral-soluble membrane agents.

Method used

Using aqueous ethanol solution as solvent, combined with hydroxypropyl methylcellulose, surfactant, plasticizer and disintegrant, a milobalbarin oral solution film is prepared. The film is formed by stirring and coating drying process. , and ensure rapid adhesion and disintegration of the drug in the oral cavity.

Benefits of technology

The milobalbarin benzenesulfonate oral membrane solvent is quickly adhered and not easily vomited in the mouth, is easy to swallow, and does not require chewing and water to take, which improves the solubility and convenience of use of drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004983297680000071
    Figure BDA0004983297680000071
  • Figure BDA0004983297680000081
    Figure BDA0004983297680000081
  • Figure BDA0004983297680000091
    Figure BDA0004983297680000091
Patent Text Reader

Abstract

The invention discloses a meloabalin besylate oral soluble film agent and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The miloabalin besylate tablet comprises the following components in parts by mass: 80-105 parts of an ethanol aqueous solution, 0.1-0.75 part of miloabalin besylate, 5-12 parts of hydroxypropyl methylcellulose, 0.1-5 parts of a surfactant, 3-10 parts of a plasticizer and 0 or 0.1-2 parts of a disintegrating agent. Compared with the defects that tablets are not easy to swallow, orally disintegrating tablets are poor in taste, easy to spit and the like in the existing dosage forms, the orally-soluble film agent medicine prepared by the invention can be quickly adhered to oral mucosa in the oral cavity, is not easy to spit out, is quickly disintegrated, is easy to swallow, does not need to be chewed and taken with water, and does not have a gravel feeling.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an orodispersible film-dissolving preparation of milobarlin besylate and a preparation method thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Mirogabalin besylate is a novel selective calcium channel α2δ ligand that can preferentially and selectively bind to the α2δ-1 subunit of voltage-dependent calcium channels (1 and 2) to exert an analgesic effect. It is mainly used to treat diabetic peripheral neuropathy, postherpetic neuralgia and fibromyalgia. Currently, the dosage form research of mirogabalin besylate is mainly focused on oral preparations, such as sustained-release tablets and orally disintegrating tablets. Oral preparations have limitations. It is difficult for the elderly, children and patients with dysphagia to take them. It is necessary to develop an orodispersible film that can be held in the mouth or placed in water and disintegrates rapidly.

[0004] Patent CN 110917164 A discloses a milobalin besylate sustained-release tablet and a preparation method thereof, but the patent does not describe an orodispersible film containing milobalin besylate.

[0005] Patent CN 116509811 A discloses a milobarlin besylate sustained-release tablet and a preparation method thereof, wherein the preparation process is simple and the obtained milobarlin besylate sustained-release tablet has good stability. However, the patent does not describe an orodispersible film containing milobarlin besylate.

[0006] Patent CN 115803020 A discloses an orally disintegrating tablet containing milobarlin besylate, which disintegrates rapidly when held in the mouth or placed in water, showing excellent solubility. However, the patent does not describe an orally disintegrating film containing milobarlin besylate. Summary of the invention

[0007] In order to solve the deficiencies of the prior art, the purpose of the present invention is to provide a milobarlin besylate orodispersible film-forming agent and a preparation method thereof. The preparation method provided by the present invention is simple and efficient, and the obtained milobarlin besylate orodispersible film-forming agent quickly adheres to the oral mucosa in the oral cavity, is not easy to spit out, is not easy to break, dissolves quickly, and is easy to swallow.

[0008] In order to achieve the above object, the technical solution of the present invention is:

[0009] The first aspect of the present invention provides a milobarlin besylate orodispersible film-forming agent, which comprises the following components in parts by mass:

[0010] 80-105 parts of ethanol aqueous solution, 0.1-0.75 parts of milobalin besylate, 5-12 parts of hypromellose, 0.1-5 parts of surfactant, 3-10 parts of plasticizer, and 0-2 parts of disintegrant.

[0011] In some embodiments of the present invention, the hypromellose is a film-forming material.

[0012] In some embodiments of the present invention, the milobalin besylate orodispersible film-forming agent uses ethanol aqueous solution as a solvent, and each 100 mL of solvent (ethanol aqueous solution) contains: 0.1-0.75 g of milobalin besylate, 5-12 g of hydroxypropyl methylcellulose, 0.1-5 g of a surfactant, 3-10 g of a plasticizer, and 0-2 g of a disintegrant.

[0013] In some embodiments of the present invention, the surfactant is selected from at least one of poloxamer, polysorbate, polyoxyethylene sorbitan monooleate, sodium lauryl sulfate, polyethylene glycol-15 hydroxystearate, polyethylene glycol, vitamin E and polyethylene glycol succinate, preferably poloxamer and polysorbate, and more preferably poloxamer 188 and polysorbate 80 (i.e., Tween 80). In addition to being a surfactant, poloxamer 188 can also be used as a solid dispersion carrier to improve the solubility of the drug (milobaline besylate).

[0014] In some embodiments of the present invention, the plasticizer is selected from at least one of glycerol, propylene glycol, polyethylene glycol 400, glycerol monooleate and glyceryl citrate, preferably glycerol, propylene glycol or polyethylene glycol 400, and more preferably glycerol.

[0015] In some embodiments of the present invention, the disintegrant is selected from at least one of lactose, soluble starch, maltodextrin, mannitol, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose and sodium alginate, preferably lactose.

[0016] In some embodiments of the present invention, the milobarlin besylate orodispersible film further comprises a flavoring agent, and the flavoring agent is selected from at least one of sucralose, citric acid hydrate, sucrose, mannitol, maltitol, stevioside, aspartame, acesulfame potassium and cyclamate, preferably a combination of sucralose and citric acid hydrate, and more preferably sucralose.

[0017] In some embodiments of the present invention, the milobarlin besylate orodispersible film-dissolving agent comprises the following components in parts by mass:

[0018] 80-105 parts of ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 5-12 parts of hypromellose, 0.1-5 parts of surfactant, 3-10 parts of plasticizer, 0-2 parts of disintegrant, and 0.1-1.2 parts of flavoring agent.

[0019] Preferably, the disintegrant is 0 or 0.1 to 2 parts.

[0020] In some embodiments of the present invention, the milobalin besylate orodispersible film-forming agent uses ethanol aqueous solution as a solvent, and each 100 mL of the solvent contains: 0.1-0.75 g of milobalin besylate, 5-12 g of hydroxypropyl methylcellulose, 0.1-5 g of a surfactant, 3-10 g of a plasticizer, 0 or 0.1-2 g of a disintegrant, and 0.1-1.2 g of a flavoring agent.

[0021] In some embodiments of the present invention, the volume ratio of water to ethanol in the ethanol aqueous solution is 4:1 to 1:4, preferably 1:1;

[0022] The milobarlin besylate orodispersible film-forming agent comprises the following components in parts by mass:

[0023] 85-90 parts of 50% ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 5-12 parts of hypromellose, 0.5-2.5 parts of poloxamer 188, 0.1-0.3 parts of polysorbate 80, 3-9 parts of glycerol, propylene glycol or polyethylene glycol 400, 0-2 parts of lactose, and 0.1-1.2 parts of sucralose.

[0024] Preferably, the lactose content is 0 or 0.1 to 2 parts.

[0025] In some embodiments of the present invention, the milobarlin besylate orodispersible film-dissolving agent comprises the following components in parts by mass:

[0026] 85-90 parts of 50% ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 9-11 parts of hypromellose, 0.5-2.5 parts of poloxamer 188, 0.1-0.3 parts of polysorbate 80, 5-9 parts of glycerol, propylene glycol or polyethylene glycol 400, 0-0.6 parts of lactose and 0.2-0.6 parts of sucralose.

[0027] Preferably, the lactose is 0 or 0.1 to 0.6 parts.

[0028] In some embodiments of the present invention, the milobarlin besylate orodispersible film-dissolving agent comprises the following components in parts by mass:

[0029] 85-90 parts of 50% ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 9-11 parts of hypromellose, 0.5-2.5 parts of poloxamer 188, 0.1-0.3 parts of polysorbate 80, 5-9 parts of glycerol, 0 or 0.1-0.6 parts of lactose, and 0.2-0.6 parts of sucralose.

[0030] In some embodiments of the present invention, the milobalin besylate orodispersible film preparation is a film-shaped preparation, and the content of the active pharmaceutical ingredient in each film is 2.5 mg to 15 mg based on milobalin besylate.

[0031] The second aspect of the present invention provides a method for preparing the milobarlin besylate orodispersible film-forming agent, comprising the following steps:

[0032] Add hydroxypropyl methylcellulose to part of the ethanol-water solution and stir until it is completely swollen;

[0033] Adding a surfactant, milobarlin besylate, a plasticizer, a disintegrant and a flavoring agent into the remaining ethanol aqueous solution and dissolving them to obtain a drug-containing solution;

[0034] Adding the drug-containing solution to completely swollen hypromellose, homogenizing, and removing bubbles to obtain a drug-containing slurry;

[0035] The drug-containing slurry is coated on the surface of the mold, dried, demoulded, and cut to obtain the product.

[0036] In some embodiments of the present invention, a surfactant, milobarlin besylate, a plasticizer, a disintegrant and a flavoring agent are added to the remaining ethanol aqueous solution to completely dissolve and disperse them, and the dispersion time is 0.5 to 2 hours.

[0037] In some embodiments of the present invention, the drug-containing solution is added to completely swollen hypromellose, stirred for homogeneity, and allowed to stand for defoaming; the stirring time is 0.5 to 2 hours, and the standing time is 0.1 to 2 hours.

[0038] There are both amino and carboxyl groups in the milobarlin besylate molecule, which may dehydrate and produce impurities when the temperature is too high, so the drying temperature should not be too high. In some embodiments of the present invention, the drying temperature is 40 to 60°C and the drying time is 0.5 to 4 hours;

[0039] Except for the drying step, the other preparation steps of the milobarlin besylate orodispersible film-dissolving agent are all carried out at room temperature or 30°C.

[0040] The beneficial effects of the present invention are:

[0041] In view of the fact that the existing milobalin besylate preparations do not involve orodispersible film preparations, the present invention proposes an orodispersible milobalin besylate film preparation and a preparation method thereof. The present invention uses hydroxypropyl methylcellulose as a film-forming material; using ethanol aqueous solution as a solvent, the drug can be fully dissolved, and the film-forming material can be fully swollen and dispersed, avoiding excessive bubbles in the drug-containing slurry, improving production efficiency, and making the appearance of the film more smooth and flat; using poloxamer 188 as a dispersion carrier, and preparing a solid dispersion with milobalin besylate, it can prevent the precipitation of granular drugs on the surface of the film after the solvent evaporates, and improve the disintegration behavior of the drug. Compared with the shortcomings of existing dosage forms such as tablets that are not easy to swallow, orally disintegrating tablets that have a poor taste and are easy to spit out, the orodispersible film preparation drug prepared by the present invention can quickly adhere to the oral mucosa when it contacts a small amount of saliva in the oral cavity, is not easy to spit out, quickly disintegrates, is easy to swallow, and does not require chewing and water delivery, and has no gravel feeling.

[0042] The preparation process of the milobarlin besylate orodispersible film-forming agent provided by the invention is simple and efficient; the milobarlin besylate orodispersible film-forming agent has a flexible dosage and can be prepared into different sizes and dosages. DETAILED DESCRIPTION

[0043] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0044] Unless otherwise specified, the reagents, methods and equipment used in the following examples are conventional reagents, methods and equipment in the art.

[0045] Example

[0046] The preparation method of milobarlin besylate orodispersible film-forming agent comprises the following steps:

[0047] (1) Dissolve the prescribed amount of hydroxypropyl methylcellulose in 50 mL of 50% ethanol aqueous solution at room temperature and stir for 30 minutes until it is completely swollen.

[0048] (2) Add the prescribed amount of poloxamer 188, Tween 80, milobarlin besylate, glycerol, lactose and sucralose to 50 mL of 50% ethanol aqueous solution at room temperature and stir for 40 min to fully dissolve and disperse them to obtain a drug-containing solution.

[0049] (3) Add the swollen film-forming material to the drug-containing solution obtained in step (2) at room temperature, stir for 30 minutes to evenly disperse, and let stand for 30 minutes to remove bubbles to obtain a drug-containing slurry.

[0050] (4) The drug-containing slurry is evenly coated on a surface dish at room temperature, dried at 60°C for 45 minutes, demolded, and cut into a size of 2.0 cm × 3.0 cm.

[0051] See Examples 1 to 24 for specific prescriptions.

[0052] Examples 1 to 3

[0053] The solvent was screened by using hydroxypropyl methylcellulose as the film-forming material, glycerol as the plasticizer, poloxamer 188 as the solid dispersion carrier, Tween 80 as the surfactant, lactose as the disintegrant, sucralose as the flavoring agent, and ethanol aqueous solution with a concentration of 20%, 50%, and 80% as the solvent, and the dosage was 100 mL. The prescription is shown in Table 1.

[0054] Table 1 Prescriptions of milobarlin besylate oral dissolving films in Examples 1 to 3

[0055]

[0056]

[0057] Embodiments 4 to 6

[0058] Hydroxypropyl methylcellulose was used as the film-forming material, glycerol was used as the plasticizer, poloxamer 188 was used as the solid dispersion carrier, Tween 80 was used as the surfactant, lactose was used as the disintegrant, sucralose was used as the flavoring agent, and 50% ethanol was used as the solvent; the models of hydroxypropyl methylcellulose were HPMC E3, HPMC E5 and HPMC E15, and the dosage was 5.0 g. The models of hydroxypropyl methylcellulose were screened, and the prescription was shown in Table 2.

[0059] Table 2 Prescriptions of milobarlin besylate oral dissolving films in Examples 4 to 6

[0060] Element Example 4 Example 5 Example 6 Milobarline Besylate 0.25g 0.25g 0.25g HPMC E3 5.0g - - HPMC E5 - 5.0g - HPMC E15 - - 5.0g glycerin 8.0g 8.0g 8.0g Poloxamer 188 2.0g 2.0g 2.0g Twain 80 0.2g 0.2g 0.2g lactose 0.5g 0.5g 0.5g Sucralose 0.5g 0.5g 0.5g 50% ethanol 100mL 100mL 100mL

[0061] Embodiments 7 to 9

[0062] Hydroxypropyl methylcellulose was used as the film-forming material, glycerol was used as the plasticizer, poloxamer 188 was used as the solid dispersion carrier, Tween 80 was used as the surfactant, lactose was used as the disintegrant, sucralose was used as the flavoring agent, and 50% ethanol was used as the solvent; the amount of HPMC E5 was 6.0-12.0 g, and the amount of hydropropyl methylcellulose was screened. The prescription is shown in Table 3.

[0063] Table 3 Prescriptions of milobarlin besylate oral dissolving films in Examples 7 to 9

[0064] Element Example 7 Example 8 Example 9 Milobarline Besylate 0.25g 0.25g 0.25g HPMC E5 6.0g 8.0g 12.0g glycerin 8.0g 8.0g 8.0g Poloxamer 188 2.0g 2.0g 2.0g Twain 80 0.2g 0.2g 0.2g lactose 0.5g 0.5g 0.5g Sucralose 0.5g 0.5g 0.5g 50% ethanol 100mL 100mL 100mL

[0065] Embodiments 10 to 12

[0066] Hydroxypropyl methylcellulose was used as the film-forming material, poloxamer 188 was used as the solid dispersion carrier, Tween 80 was used as the surfactant, lactose was used as the disintegrant, sucralose was used as the flavoring agent, 50% ethanol was used as the solvent; glycerol, propylene glycol, and polyethylene glycol 400 were used as plasticizers, and the dosage was 5.0 g, and the types of plasticizers were screened. The prescription is shown in Table 4.

[0067] Table 4 Prescription of milobalin besylate orodispersible film preparations of Examples 10 to 12

[0068]

[0069]

[0070] Embodiments 13 to 15

[0071] Hydroxypropyl methylcellulose is used as the film-forming material, poloxamer 188 is used as the solid dispersion carrier, Tween 80 is used as the surfactant, lactose is used as the disintegrant, sucralose is used as the flavoring agent, 50% ethanol is used as the solvent, and glycerol is used as the plasticizer in an amount of 3.0 to 9.0 g, and the amount of glycerol is screened. The prescription is shown in Table 5.

[0072] Table 5 Prescription of milobalin besylate orodispersible film preparations of Examples 13 to 15

[0073] Element Example 13 Embodiment 14 Embodiment 15 Milobarline Besylate 0.25g 0.25g 0.25g HPMC E5 10.0g 10.0g 10.0g glycerin 3.0g 6.0g 9.0g Poloxamer 188 2.0g 2.0g 2.0g Twain 80 0.2g 0.2g 0.2g lactose 0.5g 0.5g 0.5g Sucralose 0.5g 0.5g 0.5g 50% ethanol 100mL 100mL 100mL

[0074] Embodiments 16 to 18

[0075] Hydroxypropyl methylcellulose is used as the film-forming material, glycerol is used as the plasticizer, Tween 80 is used as the surfactant, lactose is used as the disintegrant, sucralose is used as the flavoring agent, 50% ethanol is used as the solvent; poloxamer 188 is used as the solid dispersion carrier, and the dosage is 1.0-3.0g, and the dosage is screened. The prescription is shown in Table 6.

[0076] Table 6 Prescription of milobarlin besylate orodispersible film preparations of Examples 16 to 18

[0077] Element Example 16 Embodiment 17 Embodiment 18 Milobarline Besylate 0.25g 0.25g 0.25g HPMC E5 10.0g 10.0g 10.0g glycerin 8.0g 8.0g 8.0g Poloxamer 188 0g 1.0g 3.0g Twain 80 0.2g 0.2g 0.2g lactose 0g 1.0g 2.0g Sucralose 0.5g 0.5g 0.5g 50% ethanol 100mL 100mL 100mL

[0078] Examples 19 to 21

[0079] Hydroxypropyl methylcellulose was used as the film-forming material, glycerol was used as the plasticizer, poloxamer 188 was used as the solid dispersion carrier, Tween 80 was used as the surfactant, sucralose was used as the flavoring agent, 50% ethanol was used as the solvent; lactose was used as the disintegrant in an amount of 0 to 2.0 g, and the amount of the disintegrant was screened. The prescription is shown in Table 7.

[0080] Table 7 Prescription of milobarlin besylate orodispersible film preparations of Examples 19 to 21

[0081]

[0082]

[0083] Embodiments 22 to 24

[0084] Hydroxypropyl methylcellulose was used as the film-forming material, glycerol was used as the plasticizer, poloxamer 188 was used as the solid dispersion carrier, Tween 80 was used as the surfactant, lactose was used as the disintegrant, 50% ethanol was used as the solvent; sucralose was used as the flavoring agent, and the dosage was 0.2-1.0 g, and the dosage of the flavoring agent was screened. The prescription is shown in Table 8.

[0085] Table 8 Prescription of milobarlin besylate orodispersible film preparations for Examples 19 to 21

[0086]

[0087]

[0088] The appearance, peeling property, folding resistance and disintegration time of the milobarlin besylate orodispersible films prepared in Examples 1 to 24 were examined. The criteria for the appearance evaluation are shown in Table 9.

[0089] Table 9 Appearance evaluation standards

[0090]

[0091] The peeling evaluation criteria are shown in Table 10.

[0092] Table 10 Evaluation criteria for peeling

[0093]

[0094] Folding resistance: Take the homemade milobarlin besylate orosoluble film and fold it repeatedly to the same side at an angle of 180° until it breaks. Record the number of folds when it breaks, which is the folding resistance.

[0095] Disintegration time limit: Take the homemade milobarlin besylate orodispersible film-formulation and fix it on a paper clip and put it into 37℃, 30mL distilled water. Shake it gently and record the time when the film-formulation completely disintegrates at this temperature, which is the disintegration time limit.

[0096] The test results of appearance, folding endurance, peeling property and disintegration time of Examples 1 to 24 are shown in Table 11.

[0097] Table 11 Test results of Examples 1 to 24

[0098]

[0099]

[0100]

[0101] The test results of Examples 1 to 3 show that the concentration of the solvent affects the appearance, peeling property and disintegration time of the film. When the ethanol aqueous solution of appropriate concentration is used as the solvent, the drug can be fully dissolved and excessive bubbles can be prevented from being generated after the polymer material swells, so that the film has a good appearance, appropriate folding resistance and disintegration time; the test results of Examples 4 to 9 show that the type and amount of the film-forming agent affect the folding resistance and disintegration time of the film, and the selection of a suitable film-forming agent is an important factor in the preparation process of the orally dissolving film; the test results of Examples 10 to 12 show that the type of plasticizer affects the folding resistance of the orally disintegrating film. When glycerol is used as the plasticizer, the appearance is smooth and flat without obvious bubbles. Compared with propylene glycol and polyethylene glycol 400, there is no oily substance exuding from the surface of the film; the test results of Examples 13 to 15 and Example 2 show that the plasticizer can increase the folding resistance of the film, but adding too much will lead to a prolonged disintegration time, so attention should be paid to the amount when using it; the test results of Examples 16 to 18 and Example 2 show that poloxamer 188 affects The appearance and disintegration time of the film preparation. When the addition amount is too much, the properties of the film-forming agent are affected, resulting in poor film-forming properties. An appropriate amount of poloxamer 188 can prevent the precipitation of drug particles on the surface of the film preparation after the solvent evaporates, and at the same time improve the disintegration time of the film preparation, thereby improving the drug dissolution behavior (herein, "improving drug dissolution behavior" means improving the disintegration behavior of the film preparation, which is reflected in the reduction of drug aggregation in the form of particles or lumps, so that the film preparation is better dispersed in water, thereby shortening the disintegration time. Examples 16, 17, 2, The disintegration time of Examples 18 is shortened with the increase of the amount of Poloxamer 188 used); the test results of Examples 19 to 21 and Example 2 show that the disintegration time can be shortened within a certain range, but when the amount of disintegrant is too much, it is not fully compatible with the drug-containing slurry, resulting in a rough appearance of the film and a prolonged disintegration time. Therefore, attention should be paid to the amount when using it; the test results of Examples 22 to 24 and Example 2 show that while the flavoring agent improves the taste of the film, its amount will slightly affect the appearance and other properties of the film.

[0102] In summary, the present invention relates to a milobarlin besylate orodispersible film-forming agent and a preparation method thereof. The preparation process of the method is simple and efficient. The milobarlin besylate orodispersible film-forming agent obtained by the method quickly adheres to the oral mucosa in the oral cavity and is not easy to spit out. The milobarlin besylate orodispersible film-forming agent has flexible dosage, is not easy to break, dissolves quickly, and is easy to swallow.

[0103] The milobalin besylate orodispersible film-forming agent prepared in Example 2 has a drug loading of 5 mg / tablet based on milobalin besylate. In order to prepare a 10 mg / tablet milobalin besylate orodispersible film-forming agent, the present invention adds Examples 25 to 26 for investigation.

[0104] The prescription of Example 25 is the same as that of Example 2, except that the amount of milobarlin besylate added is 0.5 g.

[0105] The recipe of Example 26 is the same as that of Example 2, except that the film is cut into a size of 3 cm×4 cm.

[0106] The test results are shown in Table 12.

[0107] Table 12 Test results of Example 25 and Example 26

[0108]

[0109] Table 12 shows that the effects of adjusting the dosage of milobarlin besylate or changing the cutting size of the film on the folding endurance, disintegration time, etc. of the film are negligible.

[0110] The drug loading range of the present invention is 2.5-15 mg, and can be made into various specifications to meet the drug needs of different drug users.

[0111] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A milobarlin besylate orodispersible film-forming agent, characterized in that: Calculated by mass, it includes the following components: 80-105 parts of ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 5-12 parts of hypromellose, 0.1-5 parts of surfactant, 3-10 parts of plasticizer, and 0-2 parts of disintegrant.

2. The milobarlin besylate orodispersible film-dissolving agent according to claim 1, characterized in that: The surfactant is selected from at least one of poloxamer, polysorbate, polyoxyethylene sorbitan monooleate, sodium lauryl sulfate, polyethylene glycol-15 hydroxystearate, polyethylene glycol, vitamin E and polyethylene glycol succinate, preferably poloxamer and polysorbate; Preferably, the plasticizer is selected from at least one of glycerol, propylene glycol, polyethylene glycol 400, glycerol monooleate and glyceryl citrate, preferably glycerol, propylene glycol or polyethylene glycol 400, and more preferably glycerol; Preferably, the disintegrant is at least one selected from lactose, soluble starch, maltodextrin, mannitol, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose and sodium alginate, preferably lactose; Preferably, the milobarlin besylate orodispersible film further comprises a flavoring agent, and the flavoring agent is selected from at least one of sucralose, citric acid hydrate, sucrose, mannitol, maltitol, stevioside, aspartame, acesulfame potassium and cyclamate, preferably a combination of sucralose and citric acid hydrate, and more preferably sucralose.

3. The milobarlin besylate orodispersible film-dissolving agent as claimed in claim 2, characterized in that: The milobarlin besylate orodispersible film-forming agent comprises the following components in parts by mass: 80-105 parts of ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 5-12 parts of hypromellose, 0.1-5 parts of surfactant, 3-10 parts of plasticizer, 0-2 parts of disintegrant, 0.1-1.2 parts of flavoring agent; Preferably, the disintegrant is 0 or 0.1 to 2 parts.

4. The milobarlin besylate orodispersible film-dissolving agent according to claim 2, wherein: The volume ratio of water to ethanol in the ethanol aqueous solution is 4:1 to 1:4, preferably 1:1; The milobarlin besylate orodispersible film-forming agent comprises the following components in parts by mass: 85-90 parts of 50% ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 5-12 parts of hypromellose, 0.5-2.5 parts of poloxamer 188, 0.1-0.3 parts of polysorbate 80, 3-9 parts of glycerol, propylene glycol or polyethylene glycol 400, 0-2 parts of lactose, and 0.1-1.2 parts of sucralose; Preferably, the lactose content is 0 or 0.1 to 2 parts.

5. The milobarlin besylate orodispersible film-dissolving agent according to claim 2, characterized in that: The milobarlin besylate orodispersible film-forming agent comprises the following components in parts by mass: 85-90 parts of 50% ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 9-11 parts of hypromellose, 0.5-2.5 parts of poloxamer 188, 0.1-0.3 parts of polysorbate 80, 5-9 parts of glycerol, propylene glycol or polyethylene glycol 400, 0-0.6 parts of lactose, and 0.2-0.6 parts of sucralose; Preferably, the lactose is 0 or 0.1 to 0.6 parts.

6. The milobarlin besylate orodispersible film-dissolving agent according to claim 2, characterized in that: The milobarlin besylate orodispersible film-forming agent comprises the following components in parts by mass: 85-90 parts of 50% ethanol aqueous solution, 0.1-0.75 parts of milobarlin besylate, 9-11 parts of hypromellose, 0.5-2.5 parts of poloxamer 188, 0.1-0.3 parts of polysorbate 80, 5-9 parts of glycerol, 0 or 0.1-0.6 parts of lactose, and 0.2-0.6 parts of sucralose.

7. The milobarlin besylate orodispersible film-dissolving agent according to claim 1, characterized in that: The milobalin besylate orodispersible film preparation is a film-shaped preparation, and the content of the active pharmaceutical ingredient in each film is 2.5 mg to 15 mg based on milobalin besylate.

8. A method for preparing the milobarlin besylate orodispersible film-dissolving agent according to any one of claims 1 to 7, characterized in that: The steps include: Add hydroxypropyl methylcellulose to part of the ethanol-water solution and stir until it is completely swollen; Adding a surfactant, milobarlin besylate, a plasticizer, a disintegrant and a flavoring agent into the remaining ethanol aqueous solution and dissolving them to obtain a drug-containing solution; Adding the drug-containing solution to completely swollen hypromellose, homogenizing, and removing bubbles to obtain a drug-containing slurry; The drug-containing slurry is coated on the surface of the mold, dried, demoulded, and cut to obtain the product.

9. The method for preparing the milopalpine besylate orodispersible film-dissolving agent as claimed in claim 8, characterized in that: Add the surfactant, milobarlin besylate, plasticizer, disintegrant and flavoring agent to the remaining ethanol aqueous solution to completely dissolve and disperse them for 0.5 to 2 hours; Alternatively, the drug-containing solution is added to completely swollen hydroxypropyl methylcellulose, stirred to homogenize, and allowed to stand to remove bubbles; the stirring time is 0.5 to 2 hours, and the standing time is 0.1 to 2 hours.

10. The method for preparing the milobarlin besylate orodispersible film-dissolving agent according to claim 8, characterized in that: The drying temperature is 40-60°C and the drying time is 0.5-4h; Except for the drying step, the other preparation steps of the milobarlin besylate orodispersible film-dissolving agent are all carried out at room temperature or 30°C.

Citation Information

Patent Citations

  • Lurasidone hydrochloride oral instant film preparation and preparation method thereof

    CN112618518A

  • Orally disintegrating tablet containing meloabalin besylate

    CN115803020A

  • Performance test system for refrigeration equipment with low-temperature heat source supply structure for water heat source / geothermal source test device

    KR1020250139611A

  • Rapidly-orodispersible tablets having an interior cavity

    TW202207905A

  • Linear polysaccharide based film products

    US20170360942A1

Cited By

  • Melogabalin besylate pharmaceutical composition and preparation method thereof

    CN120938940A